Immunic appointed biopharmaceutical veteran Michael Bonney as Chair of the Board, effective May 16, 2026, replacing interim chair Simona Skerjanec who remains as director. Bonney brings 30+ years of industry experience including leadership at Biogen during Avonex's MS launch and prior CEO role at Cubist Pharmaceuticals, which was acquired by Merck for $9.5 billion.